Key Takeaways Hologic's Molecular Diagnostics grew 7.8% in Q2 despite pressure from lost HIV testing revenues. Excluding USAID cuts, molecular sales would have seen low double-digit growth, per HOLX management. HOLX's molecular growth is fueled by innovation, including high-throughput vaginitis assays.Hologic’s (HOLX) Molecular Diagnostics business posted a 7.8% (excluding COVID-19-related sales) growth in the second quarter of fiscal 2025, although results did not reflect its full potential.The performan ...

Hologic (HOLX) 2025 Conference May 20, 2025 09:30 AM ET Speaker0 And welcome to the RBC Capital Markets twenty twenty five Global Healthcare Conference. I'm Connor McNamara, the life science tools and diagnostics analyst with RBC. It's my pleasure to welcome Hologic, and with me today is Carleen Overton, the CFO of Hologic. Carleen, thanks for joining us. Speaker1 Thanks for having me. Speaker0 I'd like to kick it off, and and I'm sorry to make this open ended, but just wanted to give you a chance to you kn ...